Overview

Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder

Status:
Recruiting

Trial end date:
2023-06-06

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the long-term safety and tolerability of cariprazine in the treatment of pediatric participants with schizophrenia or bipolar I disorder, and to establish the benefit-risk profile of long-term treatment in this population.

Phase:

Phase 3

Details

Lead Sponsor:

Allergan

Treatments:

Cariprazine